98%
921
2 minutes
20
In this narrative review, we delve into the evolving concept of brain health, as recognized by the WHO, focusing on its intersection with cognitive decline. We emphasize the imperative need for preventive strategies, particularly in older adults. We describe the target population that might benefit the most from risk-based approaches-namely, people with subjective cognitive decline. Additionally, we consider universal prevention in cognitively unimpaired middle-aged and older adults. Delving into multidomain personalized preventive strategies, we report on empirical evidence surrounding modifiable risk factors and interventions crucial in mitigating cognitive decline. Next, we highlight the emergence of brain health services (BHS). We explain their proposed role in risk assessment, risk communication, and tailored interventions to reduce the risk of dementia. Commenting on ongoing BHS pilot experiences, we present the inception and framework of our own BHS in Monza, Italy, outlining its operational structure and care pathways. We emphasize the need for global collaboration and intensified research efforts to address the intricate determinants of brain health and their potential impact on healthcare systems worldwide.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10813413 | PMC |
http://dx.doi.org/10.3390/brainsci14010055 | DOI Listing |
Neurology
September 2011
Banner Alzheimer's Institute, 901 E Willetta Street, Phoenix, AZ 85006, USA.
Arch Gen Psychiatry
August 2011
Banner Alzheimer's Institute, 901 E Willetta St., Phoenix, AZ 85006, USA.
Arch Neurol
October 2011
Division of Epidemiology, University of California, Berkeley, 94720-3190, USA.
Objective: To delineate the trajectories of Aβ42 level in cerebrospinal fluid (CSF), fludeoxyglucose F18 (FDG) uptake using positron emission tomography, and hippocampal volume using magnetic resonance imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).
Design: Cohort study.
Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.